Physician profile
Edit Tolnai
NPI 1558358630
$14,162.22
in general payments reported to CMS, 2019-2025
68 companies · $40.92 in 2025
The $40.92 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,964 · 2020: $1,825 · 2021: $3,265 · 2022: $2,834 · 2023: $3,066 · 2024: $168 · 2025: $40.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975 · Education: $216 · Long Term Medical Supply Or Device Loan: $83.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.41 |
| Education | $215.93 |
| Long Term Medical Supply Or Device Loan | $83.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,493.69 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $960.16 | 2019-2023 | Tagrisso, Lynparza, Enhertu |
| Incyte Corporation | $743.27 | 2019-2023 | Jakafi |
| Pfizer INC. | $738.54 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $727.27 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $692.53 | 2019-2023 | Darzalex, Tecvayli, Carvykti |
| Lilly USA, LLC | $678.83 | 2019-2023 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $644.18 | 2019-2023 | Kyprolis, Lumakras, Blincyto |
| E.R. Squibb & Sons, L.L.C. | $571.00 | 2019-2023 | Opdivo, Opdualag |
| Genzyme Corporation | $555.24 | 2019-2023 | |
| Celgene Corporation | $526.07 | 2019-2023 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $483.93 | 2019-2023 | Padcev, Tivdak |
| Genentech USA, INC. | $450.45 | 2019-2023 | Tecentriq, Venclexta, Alecensa |
| Eisai INC. | $407.06 | 2019-2023 | |
| Astellas Pharma US INC | $380.25 | 2019-2023 | Xtandi, Xospata |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edit Tolnai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.